고용주 및 직장용 약물 검사 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 유형별, 제품별, 모드별, 약물별, 최종 용도별, 지역별 및 경쟁(2021-2031년)

The Global Employer And Workplace Drug Testing Market is projected to expand from a valuation of USD 6.36 Billion in 2025 to USD 8.41 Billion by 2031, reflecting a compound annual growth rate of 4.77%. This market sector encompasses the laboratory services and diagnostic products used by organizations to screen their workforce for illicit substance use or medication misuse. The market's growth is fundamentally anchored by strict government safety mandates in high-risk industries and a corporate commitment to minimizing liabilities associated with workplace accidents and productivity losses. These drivers arise from core operational risk management and legal compliance necessities rather than the mere adoption of new collection technologies.

However, the expansion of the market faces a significant hurdle due to the growing complexity of cannabis legislation, which creates compliance difficulties for employers dealing with contradictory state and federal laws. This regulatory fragmentation hampers the implementation of standardized testing protocols and generates uncertainty regarding the enforcement of impairment standards. Data from the American Trucking Associations indicates that in 2024, marijuana was responsible for nearly 60% of all positive drug tests among commercial drivers, underscoring the severe challenges organizations encounter in maintaining safety protocols within this shifting legal environment.

Market Driver

Strict government mandates and regulatory compliance, alongside the urgent need for workplace safety, serve as the primary catalysts for the Global Employer And Workplace Drug Testing Market. In high-stakes sectors such as logistics and manufacturing, employers are legally obligated to enforce rigorous screening measures to prevent accidents and reduce corporate liability. This operational necessity is intensifying as safety incidents involving impairment remain a persistent threat. According to the '2025 Drug Testing Index' by Quest Diagnostics, released in September 2025, the positivity rate for post-accident drug tests in the U.S. workforce hit 10.2% in 2024, highlighting the crucial role of testing in identifying hazards following safety failures. These mandates ensure a consistent baseline of market demand that remains resilient against economic fluctuations.

Simultaneously, the market is propelled by the rising global prevalence of illicit substance use and opioid addiction, which necessitates more comprehensive and frequent screening protocols. As drug consumption increases worldwide, the risk of employee impairment rises, compelling organizations to adopt thorough testing to safeguard productivity and workforce health. The UNODC's 'World Drug Report 2024', published in June 2024, reveals that the number of people using illicit drugs globally climbed to 292 million in 2022, a 20% increase over the previous decade. The severity of this issue is further illustrated by workplace medical emergencies; according to the National Safety Council in 2025, Emergency Medical Services were activated over 12,600 times in 2024 to respond to potential opioid overdoses in workplace settings.

Market Challenge

The escalating complexity of cannabis legislation presents a formidable barrier to the growth of the Global Employer and Workplace Drug Testing Market. With states legalizing marijuana for medical and recreational use while it remains federally illegal, employers face a conflicting maze of compliance requirements. This regulatory fragmentation creates significant legal liability and uncertainty regarding impairment enforcement, particularly for non-regulated roles. Consequently, organizations are becoming risk-averse, often choosing to scale back their screening protocols or eliminate marijuana testing entirely to avoid potential lawsuits, which directly reduces test volumes and limits the adoption of diagnostic services.

The market impact of this hesitancy is evident in recent industry data showing restricted comprehensive adoption. According to the Society for Human Resource Management, in 2024, only 40% of employers reported conducting drug testing for both regulated and non-regulated roles. This figure indicates that a substantial segment of the corporate landscape is refraining from implementing full-scale screening programs. The inability to establish standardized testing policies due to legislative confusion effectively limits the market's addressable customer base and hampers revenue growth.

Market Trends

The market is being reshaped by the widespread adoption of lab-based and rapid oral fluid testing, driven by Department of Transportation approval and the necessity to detect recent use. This method mitigates the risk of specimen adulteration common in urine testing by utilizing fully observed, non-invasive collections. Employers in safety-sensitive sectors are increasingly favoring this modality to distinguish active impairment from historical cannabis use, a capability that is crucial in legalized jurisdictions. This operational shift is quantified by significant volume growth; according to First Advantage's '2024 Annual Trends Report' from August 2024, the utilization of oral fluid-based screens grew by 74% over the preceding two years, highlighting a structural pivot toward testing methods that enforce safety without penalizing off-duty conduct.

Concurrently, organizations are expanding standard drug panels to include fentanyl, addressing the gap where legacy screens fail to detect synthetic opioids. This expansion is critical as employees may pass pre-employment checks while using these substances on the job. The urgency for broader screening is highlighted by disparities in detection rates; according to Quest Diagnostics' '2025 Drug Testing Index' from September 2025, the positivity rate for fentanyl in random workforce drug tests was 707% higher than in pre-employment tests. This statistic drives the market demand for comprehensive panels capable of identifying potent synthetic compounds missed by traditional protocols.

Key Market Players

• First Advantage Corporation
• Laboratory Corporation of America Holdings
• Dragerwerk AG & Co. KGaA
• Bio-Rad Laboratories, Inc.
• Abbott Laboratories, Inc.
• Clinical Reference Laboratory Inc.
• Quest Diagnostics Inc.
• DISA Global Solutions Inc.
• HireRight, LLC
• OraSure Technologies Inc

Report Scope

In this report, the Global Employer And Workplace Drug Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Employer And Workplace Drug Testing Market, By Type

• Pre-employment Drug Screens and Post-employment

Employer And Workplace Drug Testing Market, By Product

• Consumables
• Instruments
• Rapid Testing Devices
• and Services

Employer And Workplace Drug Testing Market, By Mode

• Urine
• Hair
• Oral Fluid
• and Instant Testing

Employer And Workplace Drug Testing Market, By Drug

• Alcohol
• Cannabis/Marijuana
• Cocaine
• Opioids
• Amphetamine & Methamphetamine
• LSD
• and Others

Employer And Workplace Drug Testing Market, By End Use

• IT/Finance
• Manufacturing
• Transportation
• Construction
• Retail & Hospitality
• Healthcare
• Education
• Others

Employer And Workplace Drug Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Employer And Workplace Drug Testing Market.

Available Customizations:

Global Employer And Workplace Drug Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Employer And Workplace Drug Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Pre-employment Drug Screens and Post-employment)
  • 5.2.2. By Product (Consumables, Instruments, Rapid Testing Devices, and Services)
  • 5.2.3. By Mode (Urine, Hair, Oral Fluid, and Instant Testing)
  • 5.2.4. By Drug (Alcohol, Cannabis/Marijuana, Cocaine, Opioids, Amphetamine & Methamphetamine, LSD, and Others)
  • 5.2.5. By End Use (IT/Finance, Manufacturing, Transportation, Construction, Retail & Hospitality, Healthcare, Education, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Employer And Workplace Drug Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Mode
  • 6.2.4. By Drug
  • 6.2.5. By End Use
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Employer And Workplace Drug Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Mode
      • 6.3.1.2.4. By Drug
      • 6.3.1.2.5. By End Use
  • 6.3.2. Canada Employer And Workplace Drug Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Mode
      • 6.3.2.2.4. By Drug
      • 6.3.2.2.5. By End Use
  • 6.3.3. Mexico Employer And Workplace Drug Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Mode
      • 6.3.3.2.4. By Drug
      • 6.3.3.2.5. By End Use

7. Europe Employer And Workplace Drug Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Mode
  • 7.2.4. By Drug
  • 7.2.5. By End Use
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Employer And Workplace Drug Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Mode
      • 7.3.1.2.4. By Drug
      • 7.3.1.2.5. By End Use
  • 7.3.2. France Employer And Workplace Drug Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Mode
      • 7.3.2.2.4. By Drug
      • 7.3.2.2.5. By End Use
  • 7.3.3. United Kingdom Employer And Workplace Drug Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Mode
      • 7.3.3.2.4. By Drug
      • 7.3.3.2.5. By End Use
  • 7.3.4. Italy Employer And Workplace Drug Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Mode
      • 7.3.4.2.4. By Drug
      • 7.3.4.2.5. By End Use
  • 7.3.5. Spain Employer And Workplace Drug Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Mode
      • 7.3.5.2.4. By Drug
      • 7.3.5.2.5. By End Use

8. Asia Pacific Employer And Workplace Drug Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Mode
  • 8.2.4. By Drug
  • 8.2.5. By End Use
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Employer And Workplace Drug Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Mode
      • 8.3.1.2.4. By Drug
      • 8.3.1.2.5. By End Use
  • 8.3.2. India Employer And Workplace Drug Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Mode
      • 8.3.2.2.4. By Drug
      • 8.3.2.2.5. By End Use
  • 8.3.3. Japan Employer And Workplace Drug Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Mode
      • 8.3.3.2.4. By Drug
      • 8.3.3.2.5. By End Use
  • 8.3.4. South Korea Employer And Workplace Drug Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Mode
      • 8.3.4.2.4. By Drug
      • 8.3.4.2.5. By End Use
  • 8.3.5. Australia Employer And Workplace Drug Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Mode
      • 8.3.5.2.4. By Drug
      • 8.3.5.2.5. By End Use

9. Middle East & Africa Employer And Workplace Drug Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Mode
  • 9.2.4. By Drug
  • 9.2.5. By End Use
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Employer And Workplace Drug Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Mode
      • 9.3.1.2.4. By Drug
      • 9.3.1.2.5. By End Use
  • 9.3.2. UAE Employer And Workplace Drug Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Mode
      • 9.3.2.2.4. By Drug
      • 9.3.2.2.5. By End Use
  • 9.3.3. South Africa Employer And Workplace Drug Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Mode
      • 9.3.3.2.4. By Drug
      • 9.3.3.2.5. By End Use

10. South America Employer And Workplace Drug Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Mode
  • 10.2.4. By Drug
  • 10.2.5. By End Use
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Employer And Workplace Drug Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Mode
      • 10.3.1.2.4. By Drug
      • 10.3.1.2.5. By End Use
  • 10.3.2. Colombia Employer And Workplace Drug Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Mode
      • 10.3.2.2.4. By Drug
      • 10.3.2.2.5. By End Use
  • 10.3.3. Argentina Employer And Workplace Drug Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Mode
      • 10.3.3.2.4. By Drug
      • 10.3.3.2.5. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Employer And Workplace Drug Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. First Advantage Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Laboratory Corporation of America Holdings
• 15.3. Dragerwerk AG & Co. KGaA
• 15.4. Bio-Rad Laboratories, Inc.
• 15.5. Abbott Laboratories, Inc.
• 15.6. Clinical Reference Laboratory Inc.
• 15.7. Quest Diagnostics Inc.
• 15.8. DISA Global Solutions Inc.
• 15.9. HireRight, LLC
• 15.10. OraSure Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer